Drugs Made In Net Income
| DMAA Stock | 10.43 0.01 0.1% |
As of the 2nd of February, Drugs Made shows the Mean Deviation of 0.0775, standard deviation of 0.1103, and Coefficient Of Variation of 683.96. Drugs Made In technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Drugs Made's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Drugs Made's valuation are provided below:Drugs Made In does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. As of February 2, 2026, Net Loss is expected to decline to -0.0001. Drugs Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Drugs Made is extremely important. It helps to project a fair market value of Drugs Stock properly, considering its historical fundamentals such as Net Income. Since Drugs Made's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Drugs Made's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Drugs Made's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Diversified Capital Markets space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Drugs Made. Projected growth potential of Drugs fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Drugs Made assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Drugs Made In is measured differently than its book value, which is the value of Drugs that is recorded on the company's balance sheet. Investors also form their own opinion of Drugs Made's value that differs from its market value or its book value, called intrinsic value, which is Drugs Made's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Drugs Made's market value can be influenced by many factors that don't directly affect Drugs Made's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Drugs Made's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Drugs Made should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Drugs Made's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Drugs Made 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Drugs Made's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Drugs Made.
| 11/04/2025 |
| 02/02/2026 |
If you would invest 0.00 in Drugs Made on November 4, 2025 and sell it all today you would earn a total of 0.00 from holding Drugs Made In or generate 0.0% return on investment in Drugs Made over 90 days. Drugs Made is related to or competes with SIM Acquisition, Mountain Lake, Berto Acquisition, Centurion Acquisition, Berto Acquisition, Live Oak, and Titan Acquisition. Drugs Made is entity of United States. It is traded as Stock on NASDAQ exchange. More
Drugs Made Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Drugs Made's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Drugs Made In upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 0.1532 | |||
| Information Ratio | (0.26) | |||
| Maximum Drawdown | 0.5781 | |||
| Value At Risk | (0.1) | |||
| Potential Upside | 0.194 |
Drugs Made Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Drugs Made's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Drugs Made's standard deviation. In reality, there are many statistical measures that can use Drugs Made historical prices to predict the future Drugs Made's volatility.| Risk Adjusted Performance | 0.0502 | |||
| Jensen Alpha | 0.0059 | |||
| Total Risk Alpha | 8.0E-4 | |||
| Sortino Ratio | (0.19) | |||
| Treynor Ratio | 0.8878 |
Drugs Made February 2, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0502 | |||
| Market Risk Adjusted Performance | 0.8978 | |||
| Mean Deviation | 0.0775 | |||
| Downside Deviation | 0.1532 | |||
| Coefficient Of Variation | 683.96 | |||
| Standard Deviation | 0.1103 | |||
| Variance | 0.0122 | |||
| Information Ratio | (0.26) | |||
| Jensen Alpha | 0.0059 | |||
| Total Risk Alpha | 8.0E-4 | |||
| Sortino Ratio | (0.19) | |||
| Treynor Ratio | 0.8878 | |||
| Maximum Drawdown | 0.5781 | |||
| Value At Risk | (0.1) | |||
| Potential Upside | 0.194 | |||
| Downside Variance | 0.0235 | |||
| Semi Variance | (0.01) | |||
| Expected Short fall | (0.14) | |||
| Skewness | 0.0533 | |||
| Kurtosis | 1.52 |
Drugs Made In Backtested Returns
At this point, Drugs Made is very steady. Drugs Made In secures Sharpe Ratio (or Efficiency) of 0.14, which denotes the company had a 0.14 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Drugs Made In, which you can use to evaluate the volatility of the firm. Please confirm Drugs Made's Coefficient Of Variation of 683.96, mean deviation of 0.0775, and Standard Deviation of 0.1103 to check if the risk estimate we provide is consistent with the expected return of 0.0159%. Drugs Made has a performance score of 11 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.0069, which means not very significant fluctuations relative to the market. As returns on the market increase, Drugs Made's returns are expected to increase less than the market. However, during the bear market, the loss of holding Drugs Made is expected to be smaller as well. Drugs Made In right now shows a risk of 0.11%. Please confirm Drugs Made In treynor ratio, downside variance, kurtosis, as well as the relationship between the value at risk and expected short fall , to decide if Drugs Made In will be following its price patterns.
Auto-correlation | 0.66 |
Good predictability
Drugs Made In has good predictability. Overlapping area represents the amount of predictability between Drugs Made time series from 4th of November 2025 to 19th of December 2025 and 19th of December 2025 to 2nd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Drugs Made In price movement. The serial correlation of 0.66 indicates that around 66.0% of current Drugs Made price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.66 | |
| Spearman Rank Test | 0.89 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Drugs Made In reported net income of 0.0. This is 100.0% lower than that of the Capital Markets sector and about the same as Financials (which currently averages 0.0) industry. The net income for all United States stocks is 100.0% higher than that of the company.
Drugs Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Drugs Made's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Drugs Made could also be used in its relative valuation, which is a method of valuing Drugs Made by comparing valuation metrics of similar companies.Drugs Made is currently under evaluation in net income category among its peers.
Drugs Made ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Drugs Made's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Drugs Made's managers, analysts, and investors.Environmental | Governance | Social |
Drugs Fundamentals
| Current Valuation | 349.98 M | |||
| Shares Outstanding | 33.52 M | |||
| Shares Owned By Insiders | 26.77 % | |||
| Shares Owned By Institutions | 66.27 % | |||
| Number Of Shares Shorted | 38.66 K | |||
| Book Value Per Share | (0.22) X | |||
| Short Ratio | 5.20 X | |||
| Market Capitalization | 349.58 M |
About Drugs Made Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Drugs Made In's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Drugs Made using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Drugs Made In based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Drugs Made In is a strong investment it is important to analyze Drugs Made's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Drugs Made's future performance. For an informed investment choice regarding Drugs Stock, refer to the following important reports:Check out You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Diversified Capital Markets space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Drugs Made. Projected growth potential of Drugs fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Drugs Made assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Drugs Made In is measured differently than its book value, which is the value of Drugs that is recorded on the company's balance sheet. Investors also form their own opinion of Drugs Made's value that differs from its market value or its book value, called intrinsic value, which is Drugs Made's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Drugs Made's market value can be influenced by many factors that don't directly affect Drugs Made's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Drugs Made's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Drugs Made should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Drugs Made's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.